3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
62
Squamous Cell Carcinoma of Head and Neck
33
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Lung Neoplasms
26
Triple Negative Breast Neoplasms
21
Melanoma
19
Neoplasms
17
Breast Neoplasms
16
Neoplasm Metastasis
14
Head and Neck Neoplasms
14
Colorectal Neoplasms
14
Carcinoma, Renal Cell
14
Ovarian Neoplasms
12
Endometrial Neoplasms
12
Urinary Bladder Neoplasms
11
Carcinoma, Transitional Cell
10
Carcinoma
8
Uterine Cervical Neoplasms
7
Stomach Neoplasms
6
Sarcoma
6
Lymphoma
6
Hodgkin Disease
6
Esophageal Neoplasms
6
Recurrence
5
Pancreatic Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Multiple Myeloma
4
Mouth Neoplasms
4
Lymphoma, Non-Hodgkin
4
Laryngeal Neoplasms
4
Interventions
Temozolomide
18
Radiotherapy
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
8
Radiation
7
Lomustine
4
Nivolumab
3
Biopsy
3
trametinib
2
rocakinogene sifuplasmid
2
dabrafenib
2
cemiplimab
2
Receptors, Interleukin-8B
2
Photons
2
Palliative Care
2
Ipilimumab
2
CTLA-4 Antigen
2
vocimagene amiretrorepvec
1
veliparib
1
varlilumab
1
tinostamustine
1
temsirolimus
1
senicapoc
1
selinexor
1
relatlimab
1
regorafenib
1
perampanel
1
peposertib
1
pembrolizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
pembrolizumab
×
30 days
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts